Autonomix secures patent for nerve-targeting medical device

Photo of author
Written By Pinang Driod

THE WOODLANDS, TX – Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in nervous system diseases, announced the issuance of a new U.S. patent for its technology designed to treat cancer-related pain and augment organ function. The U.S. Patent and Trademark Office granted U.S. patent 10,143,419, which covers systems and methods including devices for treating cancerous tumors and associated pain, with an initial focus on pancreatic cancer pain.

This patent expands Autonomix’s portfolio, which already comprises over 100 issued and pending patents across 15 families. According to CEO Lori Bisson, the patent is a significant milestone in the development of their technology, which aims to provide targeted nerve therapy to patients. The company’s catheter-based sensing technology intends to detect neural signals linked to pain or disease and precisely ablate the targeted nerves in a single procedure.

The technology is poised as an alternative to current pain management approaches, which often involve systemic drugs with diminishing effectiveness and invasive procedures that may miss the target nerves. Autonomix’s solution could potentially offer a more accurate and less harmful method of treatment.

Autonomix is currently advancing toward its first human study specifically for managing pancreatic cancer pain, a market opportunity estimated to be worth billions. The company’s technology platform features a microchip sensing array that they claim is significantly more sensitive than existing technologies. While their initial focus is on pancreatic cancer pain, the technology has the potential to be applied to a variety of other conditions involving the peripheral nervous system.

Investors and industry observers note that while the issuance of the patent is a positive step for Autonomix, the company’s technology is still in development, and its effectiveness and market acceptance are yet to be proven.

This news is based on a press release statement from Autonomix Medical, Inc.

InvestingPro Insights

Autonomix Medical, Inc. (NASDAQ: AMIX) is making strides with its latest U.S. patent, yet the company’s financial metrics paint a challenging picture. A glance at the real-time data from InvestingPro shows a market capitalization of $55.29 million, reflecting the company’s current valuation in the market.

The financial health of Autonomix is a concern, as indicated by a negative P/E ratio of -4.68, which has slightly worsened to -5.09 over the last twelve months as of Q3 2024. This suggests that the company has not been profitable during this period, a detail that aligns with one of the InvestingPro Tips highlighting that AMIX has not been profitable over the last twelve months.

Investors should also note that the price of AMIX shares has experienced a significant drop, with a 46.25% decline over the last three months, which is consistent with the InvestingPro Tip mentioning a substantial fall in price over the same period. This drop in share price could be indicative of market sentiment and the perceived risks associated with the company’s development-stage technology.

While the technology’s potential is promising, the InvestingPro Tips suggest caution due to weak gross profit margins and a moderate level of debt. Additionally, the lack of dividend payments to shareholders could affect the attractiveness of AMIX as an investment for those seeking regular income.

For those considering a deeper dive into Autonomix’s prospects, InvestingPro offers additional insights. There are currently 5 more InvestingPro Tips available, which can be accessed at https://www.investing.com/pro/AMIX. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, potentially providing a more comprehensive understanding of AMIX’s financial health and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source

Leave a Comment

AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk AcUk